BOYANOV & Co. Assists Sopharma in Completing Initial Stage of Strategic Pharmaceutical Portfolio Acquisition
BOYANOV & Co. Assists Sopharma in Completing Initial Stage of Strategic Pharmaceutical Portfolio Acquisition
December 2024
Sopharma AD, Bulgaria’s leading pharmaceutical company, initiated an acquisition of a substantial portfolio comprising consumer healthcare and prescription products.
At the end of November 2024, Sopharma announced the completion of the due diligence procedures, marking the conclusion of the first stage of the acquisition. At this juncture, an amount of EUR 40 million was disbursed. The subsequent steps involve the transfer of marketing authorisations and trademarks, alongside the organisation of trading activities in the respective markets.
Our member firm, BOYANOV & Co., was instrumental in supporting Sopharma throughout the negotiation and initiation of the deal. The firm’s team was led by partners Yordan Naydenov, Peter Petrov and Borislav Notovsky, whose expertise and commitment were instrumental in achieving this milestone.
December 2024
Sopharma AD, Bulgaria’s leading pharmaceutical company, initiated an acquisition of a substantial portfolio comprising consumer healthcare and prescription products.
At the end of November 2024, Sopharma announced the completion of the due diligence procedures, marking the conclusion of the first stage of the acquisition. At this juncture, an amount of EUR 40 million was disbursed. The subsequent steps involve the transfer of marketing authorisations and trademarks, alongside the organisation of trading activities in the respective markets.
Our member firm, BOYANOV & Co., was instrumental in supporting Sopharma throughout the negotiation and initiation of the deal. The firm’s team was led by partners Yordan Naydenov, Peter Petrov and Borislav Notovsky, whose expertise and commitment were instrumental in achieving this milestone.
